NCT04707313: A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
- State
- Completed
- Phase
- Phase 2
- People
- 628 taking part
- Started
- 29 Jan 2021
- Primary completion
- 13 Sep 2023
- Arms
- PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1), PF-06882961 80 mg BID, 1-week titration (Cohort 1), PF-06882961 120 mg BID, 1-week titration (Cohort 1), PF-06882961 160 mg BID, 1-week titration (Cohort 1), PF-06882961 200 mg BID, 1-week titration (Cohort 1), PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2), PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)
- Results
- Posted on the registry
- 13 Jan 2021: Trial registered
- 29 Jan 2021: Trial started
- 11 Oct 2023: Trial completed
- 9 Oct 2024: Trial results posted